CD274 and gastric cancer: Notably, the CSCO guidelines for gastric cancer version 2022 incorporated nivolumab plus chemotherapy in class I recommendation for first-line treatment of advanced gastric cancer with CPS ≥ 5 and class II recommendation for first-line treatment of patients with CPS < 5 or inaccessible PD-L1 test, thereby further expanding the application of nivolumab in gastric cancer to the general public.